Repeat Gamma Knife surgery for recurrent trigeminal neuralgia: long-term outcomes and systematic review

Clinical article

CONSTANTIN TULEASCA, M.D., 1,4–7, ROYCE M. CARRON, M.D., PH.D., 1 NOÉMIE RÉSEQUER, M.D., M.SC., 2 ANNE DONNET, M.D., 3 PHILIPPE ROUSSEL, M.D., 1 JEAN GAUDART, M.D., PH.D., 2 MARC LEVIVIER, M.D., PH.D., 6,7, AND JEAN RÉGIS, M.D. 1

1INSERM U 751 (Université de la Méditerranée), Functional and Stereotactic Neurosurgery Unit; 2Department of Public Health and Medical Information and UMR 912 (INSERM-IRD–Université de la Méditerranée); and 3Department of Neurology, Clinical Neuroscience Federation, Centre Hospitalier Universitaire La Timone Assistance Publique–Hôpitaux de Marseille, France; 4Signal Processing Laboratory (LTS 5), École polytechnique fédérale de Lausanne; 5Medical Image Analysis Laboratory; 6Department of Clinical Neurosciences, Neurosurgery Service and Gamma Knife Center, Centre Hospitalier Universitaire Vaudois; and 7Faculty of Biology and Medicine, University of Lausanne, Switzerland

Object. The purpose of this study was to establish the safety and efficacy of repeat Gamma Knife surgery (GKS) for recurrent trigeminal neuralgia (TN).

Methods. Using the prospective database of TN patients treated with GKS in Timone University Hospital (Marseille, France), data were analyzed for 737 patients undergoing GKS for TN Type 1 from July 1992 to November 2010. Among the 497 patients with initial pain cessation, 34.4% (157/456 with ≥1-year follow-up) experienced at least 1 recurrence. Thirteen patients (1.8%) were considered for a second GKS, proposed only if the patients had good and prolonged initial pain cessation after the first GKS, with no other treatment alternative at the moment of recurrence. As for the first GKS, a single 4-mm isocenter was positioned in the cisternal portion of the trigeminal nerve at a median distance of 7.6 mm (range 4–14 mm) anterior to the emergence of the nerve (retrogasserian target). A median maximum dose of 90 Gy (range 70–90 Gy) was delivered. Data for 9 patients with at least 1-year follow-up were analyzed. A systematic review of literature was also performed, and results are compared with those of the Marseille study.

Results. The median time to retreatment in the Marseille study was 72 months (range 12–125 months) and in the literature it was 17 months (range 3–146 months). In the Marseille study, the median follow-up period was 33.9 months (range 12–96 months), and 8 of 9 patients (88.9%) had initial pain cessation with a median of 6.5 days (range 1–180 days). The actuarial rate for new hypesthesia was 33.3% at 6 months and 50% at 1 year, which remained stable for 7 years. The actuarial probabilities of maintaining pain relief without medication at 6 months and 1 year were 100% and 75%, respectively, and remained stable for 7 years. The systematic review analyzed 20 peer-reviewed studies reporting outcomes for repeat GKS for recurrent TN, with a total of 626 patients. Both the selection of the cases for retreatment and the way of reporting outcomes vary widely among studies, with a median rate for initial pain cessation of 88% (range 60%–100%) and for new hypesthesia of 33% (range 11%–80%).

Conclusions. Results from the Marseille study raise the question of surgical alternatives after failed GKS for TN. The rates of initial pain cessation and recurrence seem comparable to, or even better than, those of the first GKS, according to different studies, but toxicity is much higher, both in the Marseille study and in the published data. Neither the Marseille study data nor literature data answer the 3 cardinal questions regarding repeat radiosurgery in recurrent TN: which patients to retreat, which target is optimal, and which dose to use.

Key Words: Gamma Knife surgery • trigeminal neuralgia • retreatment • stereotactic radiosurgery

Abbreviations used in this paper: BNI = Barrow Neurological Institute; DREZ = dorsal root entry zone; GKS = Gamma Knife surgery; MVD = microvascular decompression; TN = trigeminal neuralgia.
Repeat radiosurgery for trigeminal neuralgia

cisternal part. In 1996, Kondziolka et al. published a multicenter study that established the minimal therapeu-
tic dose necessary to be effective. In 1994, Lindquist
coined the term "dorsal root entry zone (DREZ) target" (corresponding in fact to the anatomical emergence of the
trigeminal nerve). In 2000, Pollock et al. published the first paper on repeat radiosurgery for TN, and in 2006 Ré-
gis et al. published the only prospective controlled trial
using GKS as a therapy for medically unresponsive TN.

Since 1996, the number of available papers advocating
the safety and efficacy of GKS in idiopathic TN has grown continuously; however, studies describing repeat ra-
diosurgery are scarce. Furthermore, there are no clear-cut
guidelines for indication or technique for repeat radiosurg-
y, such as patient selection criteria for retreatment, dose,
location of the isocenter, or whether to plug the collimator
apertures. Therefore, we present our own study of patients
treated in Timone University Hospital, Marseille, France,
and compare our results with systematically reviewed pub-
lished data on repeat radiosurgery for recurrent TN.

Methods

Marseille Study

This was designed as an open, self-controlled, non-
comparative, retrospective study. For all patients, a case
report form was created and filled in prospectively. All patients were examined before treatment, and MR imag-
ing was performed (the latest images were used to ex-
clude any secondary cases). Permission was obtained
from the Timone University Hospital ethics committee
for this study.

Patients. Between July 1992 and November 2010, pa-
tients presenting with intractable TN were prospectively
selected and treated with radiosurgery in Timone Univer-
sity Hospital, Marseille, France. We included in our study
patients undergoing repeat GKS for recurrent TN with
more than 1 year of follow-up.

Cases of TN secondary to multiple sclerosis or due
to megadolichobasilar artery compression were exclud-
ed from our analysis, as they are reputed to have different
clinical outcomes.

All patients were treated by the senior neurosurgeon
(J.R.).

Diagnostic Criteria Using the International Head-
ache Society Definition. All patients fulfilled the TN cri-
teria of the International Headache Society. Evaluation
of the type of trigeminal pain was made according to the
classification proposed by Eller et al.: idiopathic TN
Type 1, described as typically sharp, shooting, electrical
shock-like, with pain-free intervals between the attacks,
present for more than 50% of the time; and TN Type 2,
described as an aching, throbbing, or burning pain, pre-
sent for more than 50% of the time and constant in na-
ture (constant background pain being the most significant attribute). Only patients fulfilling the criteria of the TN
Type 1 were included in the present study.

Patient Selection Criteria for Retreatment and Tech-
nique. Retreatment was proposed only if patients had good
and prolonged pain cessation after initial GKS, with no
other surgical alternative at the moment of recurrence. We
used the same target and same ranges of doses as for the
first GKS. All patients underwent repeat GKS. After appli-
cation of the Leksell Model G stereotactic frame (Elekta
AB) under local anesthesia, patients underwent stereotac-
tic MR imaging and CT imaging for target definition. The
MR image sequences used to identify the trigeminal nerve
were T2-type CISS (constructive interference in steady
state) (Siemens S.A.S.) without contrast, and contrast-enh-
hanced T1-weighted images. Bone CT imaging routinely
supplements the neuroradiological investigation to correct
any distortion errors on the MR image.

Between July 1992 and November 2010, the Gamma
Knife (model B, C, or 4C; Elekta AB) was successively
used. A single 4-mm isocenter was used in all patients,
for both the first and the second GKS, positioned in the
anterior cisternal portion of the trigeminal nerve at a me-
dian distance of 7.6 mm (range 4–14 mm) anterior to the
emergence of the nerve (retrogasserian target). This target
has been used in our center since the beginning of GKS
treatments for TN, as detailed in previous studies (Fig. 1).

The median maximum dose delivered during the
first treatment was 85 Gy (range 70–90 Gy) and at re-
treatment it was 90 Gy (range 70–90 Gy). The dose was
chosen according to the multicenter trial of Kondziolka
et al. (which included a substantial number of patients
from our center), which recommended a minimal dose of
70 Gy for short- and/or long-term efficacy, a cutoff our
group was using before the publication of that trial. Fur-
thermore, we initially give a dose of 90 Gy at the 100%
isodose. Beam channel blocking is used based on the
dose received by 10 mm³ of the brainstem: if this dose is
greater than 15 Gy, we diminish the dose and then start
plugging the collimator apertures to avoid increasing the
length of the treated nerve, which could account for more
toxicity (the so-called Flickinger effect).

Follow-Up Monitoring. Patients and referring physi-
cians were instructed to follow the pretreatment medica-
tion regimen for at least 1 month after GKS and then to
diminish the doses progressively in periods of pain free-
dom.

Initial follow-up was based on clinical evaluation at
regular intervals of 3 months, 6 months, and 1 year after
the treatment and on a yearly basis thereafter. We have
personally examined all patients for proper evaluation
of safety and efficacy, including facial sensory testing,
corneal reflex, and jaw motility. For long-term follow-up,
telephone interview was considered acceptable for pa-
tients unable to visit the clinic because of either distance
or general health-related conditions.

Every clinical evaluation made by our medical team
during follow-up was prospectively noted in the database.
The 15 items of data considered essential by Zakrzewska
and Thomas for articles reporting outcomes of surgical
treatment of TN were followed.

Explicit Definitions of Outcome Measures. Outcome
measures included initial pain cessation and onset and re-
currence of the sensory disturbance. Efficacy was classi-
fied according to the Barrow Neurological Institute (BNI) scale: Class I, no trigeminal pain, no medication; Class II, occasional pain, not requiring medication; Class IIIa, no pain with continued medication; Class IIIb, pain controlled with medication; Class IV, some pain, not adequately controlled with medication; and Class V, severe pain, no pain relief. A successfully treated patient was considered a patient who was pain free without medication (BNI Class I).

The degree of hypesthesia is reported using the BNI facial hypesthesia scale: Class I, no facial numbness; Class II, mild facial numbness, not bothersome; Class III, facial numbness, somewhat bothersome; and Class IV, facial numbness, very bothersome. The corneal reflex was assessed for all patients. Additionally, the occurrence or absence of dysesthesias, paresthesias, anesthesia dolorosa, masseter weakness, neurological complications outside the trigeminal nerve territory, systemic complications, and death were noted.

Recurrence was defined as change from Class I to a lower outcome class during follow-up. Thus, recurrence was considered to have happened in a patient who had been pain free without medication (Class I) and who then started taking specific drugs again but who remained pain free on medication (Class II).

A minor recurrence was defined as one that was well tolerated by the patient (lower frequency and intensity of the pain) and did not require additional treatment. A major recurrence was defined as one requiring a surgical procedure. We use the term “initial efficacy” when a patient is pain free with or without medication in the first 6 months after the radiosurgery and has no recurrence in the year that follows the procedure.

The latency intervals to becoming pain free or developing a recurrence or a sensory disturbance, the date of medication changes, and the date of all surgical procedures were also monitored. Patient satisfaction was evaluated at the last follow-up.

Statistical Analysis. All statistical analyses were performed using R software (version 2.12.0, R Foundation for Statistical Computing). The R package “survival” was used for survival analysis. For the evaluation of outcomes such as pain free, hypesthesia, and recurrence, time to event was estimated using the Kaplan-Meier method. A bivariate analysis was then performed to identify predictive factors among the collected variables. Qualitative variables were compared using the univariate log-rank test, with survival among the different groups represented graphically with Kaplan-Meier curves. For all variables, the effects were estimated and tested by fitting univariate Cox proportional hazards regression models. Proportionality of hazards was assessed graphically by log cumulative hazard plots. For qualitative variables, chi-square tests were performed when valid; otherwise, exact Fisher tests were used. For quantitative variables, Mann-Whitney tests were performed given the number of patients. All tests were 2-sided, and p values < 0.05 were deemed significant.

Systematic Review

Search Strategy and Selection Criteria. The PubMed database was queried using the following word combinations in the “title” item: (“repeat” AND “radiosurgery” AND “trigeminal”), (“recurrent” AND “radiosurgery” AND “trigeminal”), (“salvage” AND “radiosurgery” AND “trigeminal”). The bibliographies of the identified studies were also searched to ensure that no qualifying references were missed. Additionally, we used the Google search engine to expand our list of studies, including abstracts, but we considered in the final analysis only peer-reviewed papers. We did not restrict returns by year of publication; all published studies were eligible for selection if they fulfilled the criteria. There were no language restrictions.

Suitable studies were peer reviewed and contained data on patients who underwent repeat radiosurgery for recurrent TN, and reported rates of initial pain cessation, hypesthesia, and recurrence. Papers reporting retreatment as a subgroup were included if they had a minimum number of 13 cases, as this was the number of our study. We excluded studies that did not meet these criteria.

Three investigators (C.T., M.L., and J.R.) extracted data independently and in duplicate and assessed trial eligibility and quality. Disagreements were resolved by consensus.
Repeat radiosurgery for trigeminal neuralgia

Outcomes. We extracted the primary outcomes, initial pain cessation, hypesthesia, and recurrence, and their positive and negative predictive factors. Secondary data extracted were selection criteria and patient profile for retreatment, the number of retreatments versus the total number of patients in the same institution/trial, mean/median interval between first and second radiosurgical treatments, placement of the target and the doses used for first and second treatments, complications other than hypesthesia, and criteria used to report the outcomes.

Results

Marseille Study

Between July 1992 and November 2010, 737 patients were treated for TN at Timone University Hospital (Marseille, France). Among the 497 patients in our study with initial pain cessation after the first GKS, 34.4% (157 of 456 patients with ≥1-year follow-up) experienced at least 1 recurrence. Thirteen of the 737 patients (1.8%) had repeat GKS for recurrent TN; 9 patients with more than 1 year of follow-up were further analyzed. The median follow-up period for these 9 patients was 33.9 months (range 12–96 months). The median age at second GKS was 64.4 years (range 53.7–83.1 years). All the patients presented with typical TN Type 1 pain.

Details of Previous Treatments. Previous treatments are detailed in Table 1. All patients (100%) had prior surgical procedures, of whom 4 (44.4%) had only 1 previous intervention, 2 (22.2%) had 2 previous surgeries, and 3 (33.4%) had 3 or more previous surgeries. Previous surgeries consisted of radiofrequency lesioning in 4 patients (44.4%), balloon microcompression in 1 (11.1%), and microvascular decompression (MVD) in 1 (11.1%). Before GKS, 3 patients (33.3%) had sensory disturbance related to a previous surgical procedure, consisting of slight hypesthesia in 2 (22.2%) and severe hypesthesia in 1 (11.1%).

Initial Rate of Pain Cessation. Eight of 9 patients (88.9%) were initially pain free in a median time of 6.5 days (range 1–180 days) after retreatment and 10 days (range 1–180 days) after first GKS. The initially pain cessation actuarial rate at 0.5, 1, 2, 3, 4, 5, and 6 months was, respectively, 53.52%, 73%, 83.5%, 88.1%, 88.9%, 89.5%, and 91.3% after the first GKS (Fig. 2) and 33.3%, 44.4%, 44.4%, 55.6%, 55.6%, 66.7%, and 88.9% after retreatment. No statistically significant predictors were found for being initially pain free after the second GKS, but the small number of patients limits statistical power.

Postoperative Sensory Assessment. No patients sustained early complication after the second GKS. Three patients (33.3%) developed later objective facial sensory loss, which occurred during the 1st year after retreatment and was mild in all cases. The hypesthesia actuarial rate was 33.3% at 6 months; at 1 year it reached 50% and remained stable for 7 years (Fig. 3). For all patients with idiopathic TN treated in our institution, we have reported a hypesthesia actuarial rate of 21% after first GKS;48 in our study of patients undergoing repeat radiosurgery, we found a statistically significant higher risk of facial numbness (p = 0.0193; hazard ratio 3.97). We also assessed hypesthesia according to the BNI facial hypesthesia scale; mild facial numbness occurred in all 3 patients. No patient developed a trigeminal motor deficit or other cranial nerve deficit, or anesthesia dolorosa or dry eye syndrome after GKS. When asked about their quality of life, all patients considered the presence of hypesthesia to be a good tradeoff for the disappearance of pain. No statistically significant predictors were found for complications after the second GKS, but the small number of patients limits statistical power.

TABLE 1: Pretreatment assessment in the Marseille study (n = 9)

<table>
<thead>
<tr>
<th>Variable</th>
<th>No. of Patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>side of pain</td>
<td></td>
</tr>
<tr>
<td>right</td>
<td>6 (66.7)</td>
</tr>
<tr>
<td>left</td>
<td>3 (33.3)</td>
</tr>
<tr>
<td>no. of prior treatments</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>4 (44.4)</td>
</tr>
<tr>
<td>2</td>
<td>2 (22.2)</td>
</tr>
<tr>
<td>≥3</td>
<td>3 (33.4)</td>
</tr>
<tr>
<td>type of prior treatment</td>
<td></td>
</tr>
<tr>
<td>GKS</td>
<td>9 (100)</td>
</tr>
<tr>
<td>radiofrequency lesioning</td>
<td>4 (44.4)</td>
</tr>
<tr>
<td>balloon microcompression</td>
<td>1 (11.1)</td>
</tr>
<tr>
<td>MVD</td>
<td>1 (11.1)</td>
</tr>
<tr>
<td>side effects from prior surgery</td>
<td></td>
</tr>
<tr>
<td>normal</td>
<td>6 (60.5)</td>
</tr>
<tr>
<td>slight hypesthesia</td>
<td>2 (22.2)</td>
</tr>
<tr>
<td>severe hypesthesia</td>
<td>1 (11.1)</td>
</tr>
</tbody>
</table>

Fig. 2. Kaplan-Meier curve showing the actuarial pain cessation rates in our series after second GKS (9 patients with ≥1-year follow-up).
Management and Results of Recurrent Pain. Two patients (22.2%) who were initially pain free after GKS experienced a recurrence. The actuarial probability of maintaining pain relief without medication at 6 months was 100% and at 1 year reached 75% and remained stable for 7 years (Fig. 4). Patients with pain on the left side (p = 0.04) and in the V2 dermatome (p = 0.04) had a higher risk of recurrence. No other statistically significant predictors were found, but the small number of patients limits statistical power.

Two patients (22.2%) needed an additional treatment after GKS, with 1 surgery in 1 case (11.1%) and 3 or more surgeries in 1 case (11.1%). The further surgical procedures performed were balloon microcompression in 2 cases (22.2%) and MVD in 1 case (11.1%) (Table 2). All patients (100%) expressed a high level of satisfaction, did not regret undergoing GKS, and would undergo GKS again.

Systematic Review

Reports Included. The combination of words “repeat AND radiosurgery AND trigeminal” in PubMed database gave a number of 25 papers, from which 10 were selected,5,14,17,22,24,29,32,40,42,67 including 1 case report;29 using “recurrent AND radiosurgery AND trigeminal” returned 48 studies, from which 7 were selected;1,25–27,63,64 and using “salvage” AND “radiosurgery” AND “trigeminal” returned 1 study38 that did not report the outcomes of interest, only the range of doses used at retreatment, so we excluded it. After a detailed research of references in the included studies and after analyzing all trials published on idiopathic TN treated with GKS, 3 further studies were included, giving a total of 20 studies (Tables 3–5).

Interestingly, no dedicated study was found when searching for retreatment using linear accelerators, only sparse information without outcomes.13,57

Study Analysis. The final analysis included 20 peer-reviewed papers treating the subject of repeat GKS for TN, for a total of 626 patients. Only 4 studies contained more than 40 patients. All reports were retrospective and only 4 had long-term follow-up.32,40,62 Although this is a large number of patients, analysis was difficult because of study heterogeneity. First, the populations of patients were heterogeneous at baseline, in terms of previous surgeries (highly variable numbers and types) and inclusion of atypical cases and multiple sclerosis,1,32,63 which are reputed to have a different initial pain cessation outcomes.58 Second, there was no uniformity of patient selection criteria for retreatment. Third, outcomes were assessed differently; quality of life issues were reported sporadically24 and, if so, on

<table>
<thead>
<tr>
<th>Variable</th>
<th>No. of Patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>initially pain free</td>
<td>8 (88.9)</td>
</tr>
<tr>
<td>post-GKS sensory dysfunction</td>
<td></td>
</tr>
<tr>
<td>mild</td>
<td>3 (33.3)</td>
</tr>
<tr>
<td>severe</td>
<td>0 (0)</td>
</tr>
<tr>
<td>BNI facial hypesthesia scale (GKS related)</td>
<td></td>
</tr>
<tr>
<td>I (no facial numbness)</td>
<td>6 (66.7)</td>
</tr>
<tr>
<td>II (mild facial numbness)</td>
<td>3 (33.3)</td>
</tr>
<tr>
<td>III (facial numbness, somewhat bothersome)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>IV (facial numbness, very bothersome)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>recurrence of pain</td>
<td>2 (22.2)</td>
</tr>
<tr>
<td>no. of additional treatments after 2nd GKS</td>
<td>2 (22.2)</td>
</tr>
<tr>
<td>1</td>
<td>1 (11.1)</td>
</tr>
<tr>
<td>2</td>
<td>0 (0)</td>
</tr>
<tr>
<td>≥3</td>
<td>1 (11.1)</td>
</tr>
<tr>
<td>balloon microcompression</td>
<td>2 (22.2)</td>
</tr>
<tr>
<td>MVD</td>
<td>1 (11.1)</td>
</tr>
</tbody>
</table>
Repeat radiosurgery for trigeminal neuralgia

Outcomes were highly variable, with a median rate of initial pain cessation of 88% (range 60%–100%) after second GKS and a median hypesthesia rate of 33% (range 11%–80%).

Patient Profiles. Patients may have different response profiles to a first stereotactic radiosurgery, and they are heterogeneously represented in the literature: recurrent pain after complete response, reasonable pain control but significant medication-related side effects or partial response, or no response at all. Recurrent pain after complete response is a widely accepted indication for repeat radiosurgery; interventions for the others depend on the center’s policy. At Timone University Hospital, the patient criterion for retreatment was initial pain cessation without medication, lasting for at least 1 year.

In the published studies, the median time between first and second radiosurgery was 17 months (range 3–146 months); in the Marseille study it was 72 months (range 12–125 months; Table 3).

Technical Nuances. Technical nuances play a major role in surgical outcomes, especially regarding 2 aspects: target placement and cumulative dose. Secondary issues not specifically related to retreatment are placing 1 versus 2 isocenters, plugging (which increases the length of the treated nerve, the so-called Flickinger effect), and how the nerve recovers after a first GKS.

Target Placement. With some exceptions, most of the studies reported using the DREZ as a retreatment target, with more than 50% using the identical location the first and second time (Table 4). Some reports, such as that by Zhang et al., suggested that a longer mean distance between isocenters (2.86 vs 1.93 mm) was associated with better outcomes.

Cumulative Dose. In the studies cumulative dose was reported to range between 40 and 90 Gy at retreatment (Table 4). Cumulative dose as both a value and a cutoff for safety and efficacy remains to be defined. Its real value is not just adding the first and the second dose. Zhang et al. stated that if the dose at first GKS is 75 Gy and the dose at the second GKS is 40 Gy, with zero as the distance between isocenters, the cumulative dose would be 102 and not 115 Gy (however, biological equivalent dose has not been taken into account in this evaluation). For the same doses, but with a distance of 3 mm between the shots, Hasegawa et al. found that the cumulative dose drops to 95 Gy.

Regarding efficacy, Pollock et al. discussed the issue of a cumulative dose of 163.1 Gy versus lower doses

---

**TABLE 3: Systematic review of the literature: demographics of patients undergoing second GKS**

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>No./Total Patients</th>
<th>Center</th>
<th>Follow-Up Period in Mos (range)</th>
<th>Age in Yrs (range)</th>
<th>Mean Interval Btwn 1st &amp; 2nd GKS (mos)</th>
</tr>
</thead>
<tbody>
<tr>
<td>present study</td>
<td>13/737</td>
<td>Marseille (France)</td>
<td>median 33.9 (15.9–96)</td>
<td>median 64.4 (53.7–83.1)</td>
<td>median 72 (12–125)</td>
</tr>
<tr>
<td>Park et al., 2012</td>
<td>119/503†</td>
<td>Pittsburgh, PA (US)</td>
<td>median 48 (6–187)</td>
<td>median 74 (34–96)</td>
<td>median 26 (4–146)</td>
</tr>
<tr>
<td>Aubuchon et al., 2011</td>
<td>37</td>
<td>Florida (US)</td>
<td>mean 45.6 (7.2–86.4)</td>
<td>NA</td>
<td>mean 15.6</td>
</tr>
<tr>
<td>Jones et al., 2011</td>
<td>1</td>
<td>Seattle, WA (US)</td>
<td>24</td>
<td>72</td>
<td>11</td>
</tr>
<tr>
<td>Kimball et al., 2010</td>
<td>45/379</td>
<td>Memphis, TN (US)</td>
<td>mean 42 (1–122)</td>
<td>mean 68 (30–87)</td>
<td>mean 33 (3–138)</td>
</tr>
<tr>
<td>Verheul et al., 2010</td>
<td>79/365</td>
<td>Tilburg (the Netherlands)</td>
<td>median 28 (3–85)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Dvorak et al., 2009</td>
<td>28</td>
<td>Boston, MA (US)</td>
<td>median 19.7 (1.7–48.9)</td>
<td>median 63</td>
<td>median 18.1 (9–55.4)</td>
</tr>
<tr>
<td>Gellner et al., 2008</td>
<td>22/93</td>
<td>Graz (Austria)</td>
<td>mean 64.5 (13–142)</td>
<td>mean 73.5</td>
<td>mean 18.8 (6–63)</td>
</tr>
<tr>
<td>Huang et al., 2008</td>
<td>20/89</td>
<td>Taiwan (China)</td>
<td>mean 60 (32–87)</td>
<td>mean 61.8 (34–83)</td>
<td>mean 8 (4.67)</td>
</tr>
<tr>
<td>Wang et al., 2008</td>
<td>34/322</td>
<td>X’ian (China)</td>
<td>mean 21.6 (7–41)</td>
<td>mean 68 (42–87) at 1st GKS</td>
<td>mean 17.4 (8–34)</td>
</tr>
<tr>
<td>Huang et al., 2006</td>
<td>28/118</td>
<td>Taiwan (China)</td>
<td>median 43</td>
<td>median 63 (34–77)</td>
<td>median 8 (3–67)</td>
</tr>
<tr>
<td>Pollock et al., 2005</td>
<td>19</td>
<td>Rochester, MN (US)</td>
<td>median 24 (5–67)</td>
<td>median 68 (43–83)</td>
<td>median 16 (4–55)</td>
</tr>
<tr>
<td>Sheehan et al., 2005</td>
<td>14/151</td>
<td>Charlottesville, VA (US)</td>
<td>median 19 (after first)</td>
<td>median 68</td>
<td>NA</td>
</tr>
<tr>
<td>Urgosik et al., 2005</td>
<td>19/107</td>
<td>Prague (Czech Republic)</td>
<td>median 36 (12–72)</td>
<td>median 75 (45–91)</td>
<td>median 12.5 (3–60)</td>
</tr>
<tr>
<td>Zhang et al., 2005</td>
<td>40</td>
<td>New York (US)</td>
<td>mean 28 (6–51)</td>
<td>mean 73 (40–90)</td>
<td>mean 17 (5–48)</td>
</tr>
<tr>
<td>Herman et al., 2004</td>
<td>18/112</td>
<td>Baltimore, MD (US)</td>
<td>median 24.5 (6–65)</td>
<td>median 62 (31–89)</td>
<td>median 8 (3–42)</td>
</tr>
<tr>
<td>Brisan, 2003</td>
<td>45/335</td>
<td>Columbia, SC (US)</td>
<td>mean 15</td>
<td>mean 70</td>
<td>mean 18 (42–68)</td>
</tr>
<tr>
<td>Hasegawa et al., 2002</td>
<td>27/387</td>
<td>Pittsburgh, PA (US)</td>
<td>median 20.4</td>
<td>mean 68.7</td>
<td>mean 22.3 (6–73)</td>
</tr>
<tr>
<td>Shetter et al., 2002</td>
<td>19/240</td>
<td>Phoenix, AZ (US)</td>
<td>median 13.5</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Zheng et al., 2001</td>
<td>12/80</td>
<td>Tianjin (China)</td>
<td>mean 18</td>
<td>mean 67 (32–92)</td>
<td>NA</td>
</tr>
<tr>
<td>Pollock et al., 2000</td>
<td>10/100</td>
<td>Rochester, MN (US)</td>
<td>median 15</td>
<td>median 68 (48–83)</td>
<td>median 13 (4–27)</td>
</tr>
</tbody>
</table>

* NA = not applicable.
† The original study published in 2010 by Kondziolka et al. had 503 patients. The paper on retreatments (Park et al., 2012) does not state how many total patients they treated to that date.
(148.5 Gy in the Pittsburgh group,22 143.4 Gy in the Baltimore group,24 and 135.7 Gy in the Phoenix group54) and stated that there was higher initial pain cessation at higher doses, as much as 75% compared with a range between 19% and 53% for the lower doses.

Dvorak et al.14 proposed the concept of tailoring the dose to an individual patient. For debilitating pain they propose cumulative doses of more than 130 Gy and potentially more than 150 Gy and accepting a higher rate of side effects; for patients with reasonable pain control but medication side effects, doses less than 130 Gy seemed more appropriate, with a lower rate of side effects. Dvorak et al. mainly analyzed 7 peer-reviewed papers, accounting for 215 patients, and found an association between cumulative dose and pain control (p = 0.04) but also new dysfunction (p = 0.08); furthermore, the association between pain control and new dysfunction was strong (p = 0.02). They concluded that a dose of 130 Gy or more was more successful in terms of pain control but increased dysfunction.

Little et al.38 stated that it “seems not to be necessary to decrease the doses in patients with prior trigeminal dysfunction” and also that there is more Level III evidence for ranges of doses between 40 and 70 Gy. Hasegawa et al.22 compared combined high doses (140–160 Gy) versus lower doses (120–135 Gy) and concluded that there was no difference in recurrence rates but that there was increased hypesthesia with the higher doses (32% vs 4%). They advocated limiting the cumulative dose to 140 Gy. Herman et al.24 discussed a cumulative dose of 145 Gy (75 Gy at first GKS and 70 Gy at second GKS), with decreased efficacy but also a low incidence of facial numbness. Hasegawa et al.22 suggested that “the best dose would eliminate facial pain completely and preserve facial sensation.” To date, there is no established cut-off for dose, and there was a tendency to decrease the dose at second GKS in most studies to avoid dysfunction.

**Outcomes.** Outcomes are summarized in Table 5 and are detailed below.

* BS = brainstem; REZ = root entry zone.
† As additive value.
Repeat radiosurgery for trigeminal neuralgia

Positive predictive factors for pain cessation rates taken from the published studies are complete pain relief after initial GKS, longer periods of pain relief, reduced topographic distribution of pain after a prior GKS, new trigeminal deficits, increasing isocenter distance between second and first GKS, and higher radiation dose. Negative predictors are no pain relief after a prior GKS and having undergone prior surgical procedure(s). No correlation was found for age, sex, side, additive doses, or interval between first and second GKS (Table 6).

Hypesthesia. The median rate for new hypesthesia after repeat GKS was 33% (range 11%–80%), much higher than that reported for first GKS (6%–54%). The main problem might not even be hypesthesia per se with retreatment but such complications as bothersome hypesthesia (up to 16%), corneal numbness (up to 11%), dry eye (up to 10.9%), taste changes (up to 8.7%), jaw weakness (up to 4%), and anesthesia dolorosa (which was difficult to quantify due to heterogeneity and lack of reporting).

Positive predictive factors for new hypesthesia after second GKS, taken from the published studies, are good response to initial GKS (even at low doses), an additive dose greater than 115 Gy, isocenter placement (nearly identical location being reported by some studies as creating dysfunction), cumulative radiation dose to the lateral pons (cutoff of 44 Gy), and cumulative DREZ dose (cutoff of 84.3 Gy). No correlation was found with regard to prior surgeries, pretreatment sensory impairment, first and/or second dose or additive doses, or the distance between isocenters (considered by other studies to be a positive predictor) (Table 7).

Summarizing current literature, hypesthesia onset is suggested to be a predictor for better long-term outcome but is not mandatory for maintaining pain relief. Also, in some studies, the occurrence of hypesthesia reached rates comparable to those with radiofrequency lesioning and/or balloon microcompression. Retreatment is more injuring than a first GKS.

Maintaining Pain Relief. As with all other techniques for TN, a second GKS is not a definitive therapy. There are 2 important issues when discussing maintenance of pain relief after second GKS: one is the necessity of having long-term follow-up, as recurrences are more likely to occur 15–18 months after treatment; the second is that reported rates are fairly consistent or better compared with results of the first GKS (but there is shorter available follow-up compared with first treatment). In the published studies, recurrences ranged between 5.3% and 32% in the short term (median 24 months). Among studies reporting long-term follow-up, rates for maintaining pain relief at 5 years varied between 44.2% and 72.7%.

In the published studies, recurrences ranged between 5.3% and 32% in the short term (median 24 months). Among studies reporting long-term follow-up, rates for maintaining pain relief at 5 years varied between 44.2% and 72.7%. Additionally, in some studies, such as that by Verheul et al., the curves for first and second GKS are almost identical for this outcome.

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>Initially Pain-Free &gt;50%</th>
<th>Excellent Pain-Free (BNI Class I &amp; II)</th>
<th>Trigeminal Dysfunction</th>
<th>New Facial Numbness</th>
</tr>
</thead>
<tbody>
<tr>
<td>present study</td>
<td>89%</td>
<td>89%</td>
<td>33%</td>
<td>33.3%</td>
</tr>
<tr>
<td>Park et al., 2012</td>
<td>87%</td>
<td>32%</td>
<td>18%</td>
<td>18%</td>
</tr>
<tr>
<td>Aubuchon et al., 2011</td>
<td>81%</td>
<td>46%</td>
<td>57%</td>
<td>38%</td>
</tr>
<tr>
<td>Jones et al., 2011</td>
<td>100%</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Kimball et al., 2010</td>
<td>91.30%</td>
<td>69.5%</td>
<td>47.8%</td>
<td>45.6%; 8.7% bothersome</td>
</tr>
<tr>
<td>Verheul et al., 2010</td>
<td>96%</td>
<td>70%</td>
<td>NA</td>
<td>24%</td>
</tr>
<tr>
<td>Dvorak et al., 2009</td>
<td>61%</td>
<td>29%</td>
<td>29%</td>
<td>11%</td>
</tr>
<tr>
<td>Geliner et al., 2008</td>
<td>100.00%</td>
<td>76.2%</td>
<td>73.7%</td>
<td>73.7, 5.3% BNI III</td>
</tr>
<tr>
<td>Huang et al., 2008</td>
<td>60%</td>
<td>NA</td>
<td>NA</td>
<td>35%, 2 w/ BNI III, 1 w/ BNI IV</td>
</tr>
<tr>
<td>Wang et al., 2008</td>
<td>85.4%</td>
<td>53%</td>
<td>NA</td>
<td>11.8%, 1 as somewhat bothersome</td>
</tr>
<tr>
<td>Huang et al., 2006</td>
<td>68%</td>
<td>43%</td>
<td>36%</td>
<td>36%, 10.7 somewhat bothersome, 4% masseter weakness</td>
</tr>
<tr>
<td>Pollock et al., 2005</td>
<td>95%</td>
<td>74%</td>
<td>58%, 16% BNI III &amp; IV</td>
<td>16% BNI III &amp; IV, 11% corneal numbness</td>
</tr>
<tr>
<td>Sheehan et al., 2005</td>
<td>NA</td>
<td>NA</td>
<td>36%</td>
<td>36%</td>
</tr>
<tr>
<td>Urgosik et al., 2005</td>
<td>89%</td>
<td>58%</td>
<td>33%</td>
<td>33%</td>
</tr>
<tr>
<td>Zhang et al., 2005</td>
<td>65%</td>
<td>27%</td>
<td>10% (mainly dysesthesias), 3% severe</td>
<td>10% (mainly dysesthesias), 3% severe</td>
</tr>
<tr>
<td>Herman et al., 2004</td>
<td>88%</td>
<td>45%</td>
<td>11%, 5.5% BNI III &amp; IV</td>
<td>11%, 5.5% BNI III &amp; IV</td>
</tr>
<tr>
<td>Brisman, 2003</td>
<td>62%</td>
<td>22%</td>
<td>4% severe dysesthesias</td>
<td>8.8% BNI III, 4.4% BNI IV</td>
</tr>
<tr>
<td>Shetter et al., 2002</td>
<td>88%</td>
<td>53%</td>
<td>12.7%</td>
<td>12.7%</td>
</tr>
<tr>
<td>Hasegawa et al., 2002</td>
<td>85.2%</td>
<td>18.5%</td>
<td>11%</td>
<td>11%</td>
</tr>
<tr>
<td>Zheng et al., 2001</td>
<td>91.7%</td>
<td>75%</td>
<td>80%</td>
<td>80%</td>
</tr>
<tr>
<td>Pollock et al., 2000</td>
<td>90%</td>
<td>90%</td>
<td>80%</td>
<td>80%</td>
</tr>
</tbody>
</table>

TABLE 5: Systematic review of the literature: results of second GKS
TABLE 6: Systematic review of the literature: predictors of initial pain cessation after second GKS

<table>
<thead>
<tr>
<th>positive predictors</th>
<th>negative predictors</th>
</tr>
</thead>
<tbody>
<tr>
<td>initial complete pain relief after a prior GKS</td>
<td>no pain relief after a prior GKS</td>
</tr>
<tr>
<td>longer periods of pain relief after 1st GKS</td>
<td>prior surgical procedure</td>
</tr>
<tr>
<td>reduced distribution after 1st GKS</td>
<td>no correlation</td>
</tr>
<tr>
<td>new trigeminal deficits</td>
<td>age</td>
</tr>
<tr>
<td>increasing distance between isocenters of 1st &amp; 2nd radiation dose</td>
<td>sex</td>
</tr>
</tbody>
</table>

Positive predictive factors were partial recurrence after first GKS (partial better than complete), recurrence in a reduced topographic distribution, and additional sensory dysfunction after a first treatment.32

Discussion

Medically unresponsive TN can be treated by 3 methods: MVD, percutaneous techniques, and GKS. With the MVD technique, Barker et al.2 reported up to 70% of patients remaining pain free at 10 years; for patients undergoing repeat MVD, 42% of cases had excellent results at 10 years. Depending on the study, MVD recurrence rates on long-term basis range between 15% and 35%.2–4,7,8,10–12,18,28,30,52,55,56 For percutaneous techniques, such as thermocoagulation, some trials reported a 57.7% pain-free response after a first procedure and up to 94% at 5-year follow-up after a second procedure.31 Facial numbness has been reported to occur in between 58% and 79% of patients.9,65 Gybels and Sweet9 reviewed 8 published studies on thermocoagulation, involving more than 600 procedures; corneal numbness ranged from 1% to 35% and anesthesia dolorosa, from 0.6% to 25%.

Repeat radiosurgery emerged as an alternative to these 2 techniques, especially during the last 10 years. A number of clinical retrospective trials have shown that second GKS is a safe and effective procedure, with comparable or better initial pain cessation rates, despite a higher toxicity, which seems to be the tradeoff for maintaining pain relief.1,5,14,17,22–27,32,38,42,63 Nevertheless, there is little consistent information to counsel patients on an individual basis, due to heterogeneity among papers regarding selection criteria and treatment parameters.

Among the 497 patients included in our study with initial pain cessation after the first GKS, 34.4% (157 of 456 with ≥ 1-year follow-up) experienced at least 1 recurrence; 112 of 157 required further treatment. Thirteen (1.8%) of the 737 patients were considered for a second GKS, a rate smaller than found in the published peer-reviewed papers, which ranged in from 7%22 to 23.7%26 (Table 3); this is explained by a different strategy of repeat GKS in our study.

Patient selection for retreatment is probably one of the most important issues. Why to retreat, when to retreat, and the patient profile are key conditions for therapeutic success. Our center uses strict selection criteria for second GKS, related to an initial and prolonged pain cessation without medication, in the absence of other surgical alternatives. This is suggested by the median time for retreatment in our study, 72 months (range 12–125 months), compared with 17 months (range 12–125 months) in the literature reviewed. Also, previous studies discussing first GKS showed improved outcomes with no atypical features.39,44 No prior surgical treatment,6,39,41 or no new trigeminal deficits.5,44 When reporting outcomes, we believe that these types of cases should be clearly separated.

Additionally, individual patient sensitivity to irradiation might play a role. We might be selecting a subgroup of patients sensitive to radiation when treating only those responding well to the first GKS.

Another issue is related to doses. For GKS, a minimum dose of 70 Gy necessary for efficacy was established in 1996 by a multicenter trial.34 As a maximum, in a baboon model Kondziolka et al.34 suggested that necrosis occurred at 100 Gy. In this range, higher doses are related to better efficacy.51,64 Thus, our policy is to deliver 90 Gy at 100% isodose, whenever the morphology of the cistern allows this dose prescription, while keeping doses to the brainstem low. This dose allows a low rate of toxicity, provided that we use the retrogasserian target (7–8 mm from the emergence).48 We kept the same dose and the same target placement at first and second GKS.

The radiation target is important with respect to initial pain cessation and side effects. The heterogeneity regarding radiation target in published studies makes the “ideal” target difficult to establish.

Current literature is sparse, and there is a need for more follow-up and uniformity to establish state-of-the-
Repeat radiosurgery for trigeminal neuralgia

art safety and efficacy for GKS retreatment. Pain control and recurrence rates seem comparable with first GKS in the literature we reviewed, with higher hypesthesia rates at second GKS in almost all studies. When investigating safety and efficacy, particular attention should be paid to individual patient characteristics at baseline, as well as to technical nuances, mainly target placement and radiation dose; additionally, the number of patients and duration of follow-up are important criteria.

Besides the relatively small sample size, our study raises the question of surgical alternatives after failed GKS for TN. The rates of initial pain cessation and recurrence seem comparable to or even better than those for the first GKS, according to different studies, but the toxicity is much higher, both in our study and in the published data. However, because of the small number of patients in our study and limited available follow-up and heterogeneity of treatment philosophies in the reviewed studies, we do not have the answer to the 3 cardinal questions regarding repeat radiosurgery in recurrent TN: which patients to retreat, which target is optimal, and which dose is optimal. Reassessment of our database in 20 years’ time may offer sufficient numbers to answer these questions.

Conclusions

Our study is small compared with our general cohort due to very strict selection criteria for retreatment, mainly related to an initial and prolonged pain cessation without medication, in the absence of other surgical alternatives. Our study is differentiated from the other published studies by the use of the same technical parameters as the first GKS and much longer delay between first and second GKS, with a median of 72 months (range 12–125 months) at our institution compared with 17 months (range 3–146 months) in the literature. Current available studies suggest that second GKS is safe and effective, with an important increase in hypesthesia rates. Our attitude, due to this higher toxicity, is to propose MVD as a first intention therapy for recurrent TN after first GKS and to reserve second GKS for cases with no other surgical alternative.

Disclosure

This study received funding from Timone University Hospital, Assistance-Publique, Hôpitaux de Marseille, France. Dr. Régis received congress organization sponsoring from Accuray, Brainlab, Elekta, and Varian. The other authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author contributions to the study and manuscript preparation include the following. Conception and design: Tuleasca, Levivier, Régis. Acquisition of data: Tuleasca, Donnet, Roussel, Régis. Analysis and interpretation of data: Tuleasca, Carron, Donnet, Roussel, Levivier, Régis. Drafting the article: Tuleasca. Critically revising the article: Tuleasca, Carron, Donnet, Levivier, Régis. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Tuleasca. Statistical analysis: Resseguier, Gaudart. Administrative/technical/material support: Levivier, Régis. Study supervision: Levivier, Régis.

References

21. Håkanson S: Trigeminal neuralgia treated by the injection of
59. Tuleasca C, Carron R, Resseguiuer N, Donnet A, Roussel P,
Repeat radiosurgery for trigeminal neuralgia


Manuscript submitted June 29, 2014. Accepted August 1, 2014. Please include this information when citing this paper: DOI: 10.3171/2014.8.GKS141487.

Address correspondence to: Constantin Tuleasca, M.D., Lausanne University Hospital, Neurosurgery Service and Gamma Knife Center, Rue de Bugnon 44-46, BH-08, CH-1011 Lausanne, Switzerland. email: constantin.tuleasca@gmail.com.